HIV Drug Resistance Genotyping PT Program

The HIV-1 Drug Resistance Sequencing Proficiency Testing program assesses the proficiency of NIAID-supported and other interested research laboratories at correctly identifying drug resistant mutations and concentrations in samples collected, processed, and characterized by the Duke VQA team. Each site will be asked to perform 2 PT panels throughout the year, each consisting of 5 samples from HIV culture supernatant spiked into base matrix diluent. 

 

PT panels will include HIV-1 with known Protease (PR; amino acids 9-91) and Reverse Transcriptase (RT; amino acids 40-237) or integrase (INT; amino acids 50-200) gene drug resistant mutations. Laboratory submitted sequences are scored against a consensus reference sequence. A nucleotide position is included in the consensus only if there is at least 80% agreement for that position among all of the laboratories. 

Laboratories are not to share information regarding kit components or their results with other laboratories until the study is completed and the final data has been analyzed. Laboratories should run their EP in their own laboratory and should not subcontract out testing.  Participating laboratories will be blinded with a unique VQA site ID.  Each laboratory will be unblinded with respect to only their datasets. Sites can only report results for their site.